Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-naïve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipo - protein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-naïve group, and glycosylated haemoglobin (HbA1c) had not changed significantly in either group. Study 2 was a retrospective investigation of 87 outpatients with hyper cholesterolaemia who had been taking atorvastatin for at least 4 years. Compared with baseline (patients who had taken atorvastatin for at least 1 year), total cholesterol and triglyceride levels did not change over the study period, HDL-C increased significantly at 2 and 3 years, HbA1c was significantly decreased at 1, 2 and 3 years and serum creatinine was significantly decreased at 1 year. Atorvastatin lowered LDL-C concentration, did not worsen glycaemic control and might improve renal function in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)1504-1512
Number of pages9
JournalJournal of International Medical Research
Volume39
Issue number4
DOIs
Publication statusPublished - 2011 Jan 1
Externally publishedYes

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kidney
Cholesterol
HDL Cholesterol
Outpatients
Glycosylated Hemoglobin A
Hypercholesterolemia
Glomerular Filtration Rate
Creatinine
Triglycerides
Proteins
Atorvastatin Calcium
Serum

Keywords

  • 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
  • Atorvastatin
  • Glycaemic control
  • Hypercholesterolaemia
  • Renal function
  • Statins
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes. / Tanaka, M.

In: Journal of International Medical Research, Vol. 39, No. 4, 01.01.2011, p. 1504-1512.

Research output: Contribution to journalArticle

@article{7a654a442bef44d1964e5dc96d4c9f2e,
title = "Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes",
abstract = "Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-na{\"i}ve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipo - protein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-na{\"i}ve group, and glycosylated haemoglobin (HbA1c) had not changed significantly in either group. Study 2 was a retrospective investigation of 87 outpatients with hyper cholesterolaemia who had been taking atorvastatin for at least 4 years. Compared with baseline (patients who had taken atorvastatin for at least 1 year), total cholesterol and triglyceride levels did not change over the study period, HDL-C increased significantly at 2 and 3 years, HbA1c was significantly decreased at 1, 2 and 3 years and serum creatinine was significantly decreased at 1 year. Atorvastatin lowered LDL-C concentration, did not worsen glycaemic control and might improve renal function in patients with type 2 diabetes.",
keywords = "3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, Atorvastatin, Glycaemic control, Hypercholesterolaemia, Renal function, Statins, Type 2 diabetes",
author = "M. Tanaka",
year = "2011",
month = "1",
day = "1",
doi = "10.1177/147323001103900440",
language = "English",
volume = "39",
pages = "1504--1512",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "4",

}

TY - JOUR

T1 - Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes

AU - Tanaka, M.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-naïve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipo - protein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-naïve group, and glycosylated haemoglobin (HbA1c) had not changed significantly in either group. Study 2 was a retrospective investigation of 87 outpatients with hyper cholesterolaemia who had been taking atorvastatin for at least 4 years. Compared with baseline (patients who had taken atorvastatin for at least 1 year), total cholesterol and triglyceride levels did not change over the study period, HDL-C increased significantly at 2 and 3 years, HbA1c was significantly decreased at 1, 2 and 3 years and serum creatinine was significantly decreased at 1 year. Atorvastatin lowered LDL-C concentration, did not worsen glycaemic control and might improve renal function in patients with type 2 diabetes.

AB - Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-naïve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipo - protein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-naïve group, and glycosylated haemoglobin (HbA1c) had not changed significantly in either group. Study 2 was a retrospective investigation of 87 outpatients with hyper cholesterolaemia who had been taking atorvastatin for at least 4 years. Compared with baseline (patients who had taken atorvastatin for at least 1 year), total cholesterol and triglyceride levels did not change over the study period, HDL-C increased significantly at 2 and 3 years, HbA1c was significantly decreased at 1, 2 and 3 years and serum creatinine was significantly decreased at 1 year. Atorvastatin lowered LDL-C concentration, did not worsen glycaemic control and might improve renal function in patients with type 2 diabetes.

KW - 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

KW - Atorvastatin

KW - Glycaemic control

KW - Hypercholesterolaemia

KW - Renal function

KW - Statins

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=80052232669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052232669&partnerID=8YFLogxK

U2 - 10.1177/147323001103900440

DO - 10.1177/147323001103900440

M3 - Article

C2 - 21986154

AN - SCOPUS:80052232669

VL - 39

SP - 1504

EP - 1512

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 4

ER -